BudesonideGlycopyrroniumFormoterolQualityChecker

Budesonide/Glycopyrronium/Formoterol Quality Checker

Asthma COPD CSV→JSON FDC Inhaler MissingAPI P1 QC
Open selection
Budesonide/Glycopyrronium/Formoterol Quality Checker — Triple Inhaler (ICS/LAMA/LABA) Quality Control

ℹ️ Utility checks critical parameters of triple combination (ICS/LAMA/LABA):
• Budesonide Content: 144–198 mcg/dose
• Glycopyrronium Content: 7.2–10.8 mcg/dose
• Formoterol Content: 3.6–5.4 mcg/dose
• Fine Particle Fraction (FPF): ≥15%
• Dose Uniformity: deviation ≤15%
• Moisture Content: ≤1.0%
• Impurities: ≤1.5%
• Valve Leak Rate: ≤0.5 mL/min
• Actuator Force: 15–25 N

⚠️ CRITICAL: Low fine particle fraction reduces delivery of all three components to the lungs.
Violation of dosage of any component reduces COPD/asthma therapy efficacy.

Usage:
BudesonideGlycopyrroniumFormoterolQualityChecker.exe → demo mode
BudesonideGlycopyrroniumFormoterolQualityChecker.exe input.csv output.json → evaluate data

Input format:
BatchNumber,BudesonideAssay,GlycopyrroniumAssay,FormoterolAssay,FineParticleFraction,DDUDeviation,Moisture,Impurities,ValveLeak,ActuatorForce

Example:
BGF-2026-001,160.0,9.0,4.5,20.5,7.0,0.4,0.7,0.2,19.0

— WHY IS THIS NEEDED?
Triple combination of budesonide (ICS), glycopyrronium (LAMA), and formoterol (LABA) is used for treating severe asthma and COPD:
• Budesonide — corticosteroid, reduces inflammation
• Glycopyrronium — long-acting anticholinergic, bronchodilator
• Formoterol — long-acting beta-agonist, smooth muscle relaxant
• Combination of three mechanisms provides maximum symptom control
• Inhalation form requires strict control of aerodynamic properties

⚠️ CRITICAL:
• Component content must be within a narrow range for therapeutic effect
• Fine Particle Fraction (FPF) determines the fraction of drug reaching alveoli
• Dose uniformity is critical for patient safety with each inhalation
• Moisture affects powder flowability and valve operation
• System tightness prevents drug loss and contamination

Key features:
• Comprehensive check of three active substances with different mechanisms of action
• Control of aerodynamic parameters (FPF)
• Assessment of mechanical device characteristics (valve, actuator)
• Stability check of composition (moisture, impurities)

Critical parameters:
• Budesonide Assay: 144–198 mcg/dose
• Glycopyrronium Assay: 7.2–10.8 mcg/dose
• Formoterol Assay: 3.6–5.4 mcg/dose
• Fine Particle Fraction: ≥15%
• Dose Uniformity Deviation: ≤15%
• Moisture Content: ≤1.0%
• Total Impurities: ≤1.5%
• Valve Leak Rate: ≤0.5 mL/min
• Actuator Force: 15–25 N

💡 Usage tips:
1. Content determined by HPLC after extraction from inhaler
2. Fine Particle Fraction measured using cascade impactor (USP <601>)
3. Dose uniformity tested on a series of inhalations
4. Moisture controlled by Karl Fischer method
5. Tightness checked on specialized leak testers

⚠️ Note: Triple inhalers represent the pinnacle of complexity in respiratory drug development. Balance between three different molecules, their physicochemical properties, and particle aerodynamics requires precision control. Any deviation in dosage or particle size can significantly reduce clinical efficacy of therapy.

input.csv

BatchNumber,BudesonideAssay,GlycopyrroniumAssay,FormoterolAssay,FineParticleFraction,DDUDeviation,Moisture,Impurities,ValveLeak,ActuatorForce
BGF-2026-001,160.0,9.0,4.5,20.5,7.0,0.4,0.7,0.2,19.0
BGF-2026-002,155.0,8.5,4.2,18.0,8.5,0.5,0.9,0.3,18.5

BudesonideGlycopyrroniumFormoterolQualityChecker — Documentation

Bilingual RU/EN URS & FS. Source: input.csv and *.description.txt. Package folder: Global/API coverage extension.
Utility
BudesonideGlycopyrroniumFormoterolQualityChecker
Package
Global/API coverage extension
CSV fields
10
Interface
CSV → JSON

Utility description

Budesonide/Glycopyrronium/Formoterol Quality Checker — Triple Inhaler (ICS/LAMA/LABA) Quality Control

ℹ️  Utility checks critical parameters of triple combination (ICS/LAMA/LABA):
    • Budesonide Content: 144–198 mcg/dose
    • Glycopyrronium Content: 7.2–10.8 mcg/dose
    • Formoterol Content: 3.6–5.4 mcg/dose
    • Fine Particle Fraction (FPF): ≥15%
    • Dose Uniformity: deviation ≤15%
    • Moisture Content: ≤1.0%
    • Impurities: ≤1.5%
    • Valve Leak Rate: ≤0.5 mL/min
    • Actuator Force: 15–25 N

⚠️  CRITICAL: Low fine particle fraction reduces delivery of all three components to the lungs.
    Violation of dosage of any component reduces COPD/asthma therapy efficacy.

Usage:
  BudesonideGlycopyrroniumFormoterolQualityChecker.exe                            → demo mode
  BudesonideGlycopyrroniumFormoterolQualityChecker.exe input.csv output.json      → evaluate data

Input format:
BatchNumber,BudesonideAssay,GlycopyrroniumAssay,FormoterolAssay,FineParticleFraction,DDUDeviation,Moisture,Impurities,ValveLeak,ActuatorForce

Example:
  BGF-2026-001,160.0,9.0,4.5,20.5,7.0,0.4,0.7,0.2,19.0

— WHY IS THIS NEEDED?
Triple combination of budesonide (ICS), glycopyrronium (LAMA), and formoterol (LABA) is used for treating severe asthma and COPD:
• Budesonide — corticosteroid, reduces inflammation
• Glycopyrronium — long-acting anticholinergic, bronchodilator
• Formoterol — long-acting beta-agonist, smooth muscle relaxant
• Combination of three mechanisms provides maximum symptom control
• Inhalation form requires strict control of aerodynamic properties

⚠️  CRITICAL:
• Component content must be within a narrow range for therapeutic effect
• Fine Particle Fraction (FPF) determines the fraction of drug reaching alveoli
• Dose uniformity is critical for patient safety with each inhalation
• Moisture affects powder flowability and valve operation
• System tightness prevents drug loss and contamination

Key features:
• Comprehensive check of three active substances with different mechanisms of action
• Control of aerodynamic parameters (FPF)
• Assessment of mechanical device characteristics (valve, actuator)
• Stability check of composition (moisture, impurities)

Critical parameters:
• Budesonide Assay: 144–198 mcg/dose
• Glycopyrronium Assay: 7.2–10.8 mcg/dose
• Formoterol Assay: 3.6–5.4 mcg/dose
• Fine Particle Fraction: ≥15%
• Dose Uniformity Deviation: ≤15%
• Moisture Content: ≤1.0%
• Total Impurities: ≤1.5%
• Valve Leak Rate: ≤0.5 mL/min
• Actuator Force: 15–25 N

💡 Usage tips:
1. Content determined by HPLC after extraction from inhaler
2. Fine Particle Fraction measured using cascade impactor (USP <601>)
3. Dose uniformity tested on a series of inhalations
4. Moisture controlled by Karl Fischer method
5. Tightness checked on specialized leak testers

⚠️ Note: Triple inhalers represent the pinnacle of complexity in respiratory drug development. Balance between three different molecules, their physicochemical properties, and particle aerodynamics requires precision control. Any deviation in dosage or particle size can significantly reduce clinical efficacy of therapy.

URS & FS — User Requirements and Functional Specification

This document describes the controlled interface and behaviour of BudesonideGlycopyrroniumFormoterolQualityChecker for Budesonide/Glycopyrronium/Formoterol Quality Checker.

Portal packages

Global/API coverage extension, LabEx QC laboratory utilities, Lumex QC instrument utilities, Medical Gases / inhaler-adjacent QC Suite, World API/FDC extension

AsthmaCOPDCSV→JSONFDCInhalerMissingAPIQCRespiratoryURS & FSP1

Domain limits and critical parameters

Key fragments from the source description are shown below. Before production use, limits must be verified against the approved specification, registration dossier and local SOPs.
  • ℹ️ Utility checks critical parameters of triple combination (ICS/LAMA/LABA):
  • • Budesonide Content: 144–198 mcg/dose
  • • Glycopyrronium Content: 7.2–10.8 mcg/dose
  • • Formoterol Content: 3.6–5.4 mcg/dose
  • • Fine Particle Fraction (FPF): ≥15%
  • • Dose Uniformity: deviation ≤15%
  • • Moisture Content: ≤1.0%
  • • Impurities: ≤1.5%
  • • Valve Leak Rate: ≤0.5 mL/min
  • ⚠️ CRITICAL: Low fine particle fraction reduces delivery of all three components to the lungs.
  • BatchNumber,BudesonideAssay,GlycopyrroniumAssay,FormoterolAssay,FineParticleFraction,DDUDeviation,Moisture,Impurities,ValveLeak,ActuatorForce
  • ⚠️ CRITICAL:
  • • Component content must be within a narrow range for therapeutic effect
  • • Dose uniformity is critical for patient safety with each inhalation
  • • Stability check of composition (moisture, impurities)
  • Critical parameters:
  • • Budesonide Assay: 144–198 mcg/dose
  • • Glycopyrronium Assay: 7.2–10.8 mcg/dose

URS — User Requirements Specification

IDRequirementCriticalityAcceptance criterion
URS-001The utility shall accept an input.csv file for Budesonide/Glycopyrronium/Formoterol Quality Checker with headers defined in the data contract.HighThe file is processed without manual header editing.
URS-002The utility shall perform deterministic QC evaluation without machine learning and without probabilistic conformance decisions.HighIdentical input data, rule version and configuration produce reproducible results.
URS-003The utility shall validate mandatory fields, data types, ranges, units and domain plausibility.HighSchema, conversion and range errors are explicitly reported.
URS-004The utility shall apply domain limits and rules from the description, approved specification, registration dossier and local SOPs.HighEach check has PASS/WARNING/FAIL and a clear message.
URS-005The utility shall generate output.json with machine-readable results, source values, warnings, failures and critical findings.HighJSON is suitable for LIMS/ELN/MES integration and QA/QC review.
URS-006The utility shall preserve traceability between batch/sample, input file, applied rules and final status.HighOutput contains identifiers, checked parameters and audit metadata.
URS-007The documentation shall support IQ/OQ/PQ, CSV/CSA and review by internal QA or inspectors.MediumURS, FS, input/output contract and test scenarios are supplied with the utility.
URS-008The utility shall be used as a QC decision-support tool and not as a substitute for approved specifications and QA/QP release decision.MediumDocumentation states change control and limit-verification expectations.

input.csv contract

#FieldTypeSamplePurpose
1BatchNumberstring / controlled vocabularyBGF-2026-001Batch or lot identifier used for traceability.
2BudesonideAssaydecimal160.0Quantitative content/potency; critical release parameter.
3GlycopyrroniumAssaydecimal9.0Quantitative content/potency; critical release parameter.
4FormoterolAssaydecimal4.5Quantitative content/potency; critical release parameter.
5FineParticleFractiondecimal20.5Size/particle attribute; physicochemical quality parameter.
6DDUDeviationdecimal7.0Controlled input parameter for deterministic QC rules.
7Moisturedecimal0.4Moisture/water parameter relevant to stability.
8Impuritiesdecimal0.7Impurity/related-substance parameter; purity and degradation control.
9ValveLeakdecimal0.2Controlled input parameter for deterministic QC rules.
10ActuatorForcedecimal19.0Controlled input parameter for deterministic QC rules.
BatchNumber,BudesonideAssay,GlycopyrroniumAssay,FormoterolAssay,FineParticleFraction,DDUDeviation,Moisture,Impurities,ValveLeak,ActuatorForce
BGF-2026-001,160.0,9.0,4.5,20.5,7.0,0.4,0.7,0.2,19.0
BGF-2026-002,155.0,8.5,4.2,18.0,8.5,0.5,0.9,0.3,18.5

Input validation rules

IDFieldRuleCriticality
VR-001BatchNumberThe field shall match an approved dictionary or accepted string representation.High
VR-002BudesonideAssayThe value shall be numeric, non-empty and domain-plausible for the approved specification.High
VR-003GlycopyrroniumAssayThe value shall be numeric, non-empty and domain-plausible for the approved specification.High
VR-004FormoterolAssayThe value shall be numeric, non-empty and domain-plausible for the approved specification.High
VR-005FineParticleFractionThe value shall be numeric, non-empty and domain-plausible for the approved specification.Medium
VR-006DDUDeviationThe value shall be numeric, non-empty and domain-plausible for the approved specification.Medium
VR-007MoistureThe value shall be numeric, non-empty and domain-plausible for the approved specification.Medium
VR-008ImpuritiesThe value shall be numeric, non-empty and domain-plausible for the approved specification.High
VR-009ValveLeakThe value shall be numeric, non-empty and domain-plausible for the approved specification.Medium
VR-010ActuatorForceThe value shall be numeric, non-empty and domain-plausible for the approved specification.Medium

FS — Functional Specification

IDFunctionImplementation
FS-001CLI executionSupport execution modes: demo mode without arguments and production mode input.csv output.json.
FS-002CSV importRead input.csv in UTF-8/CSV-compatible format and validate header and expected columns.
FS-003Schema validationCheck mandatory fields, column count, unknown key fields and empty mandatory values.
FS-004Type conversionConvert numeric, flag and text values; invalid format is recorded as a row-level error.
FS-005Domain rule engineApply rules for Budesonide/Glycopyrronium/Formoterol Quality Checker, including critical limits from the description and approved specification.
FS-006Status aggregationProduce final status: FAIL for critical failure, WARNING for non-critical deviation, PASS for conformance.
FS-007JSON exportWrite output.json with detailed checks, source values, warnings, failures and critical findings.
FS-008Audit supportKeep result structure suitable for review, deviation investigation and calculation reproduction.
FS-009Integration contractSupport the scenario LIMS/ELN/MES → input.csv → utility → output.json → portal/admin review.
FS-010Fallback mappingIf the combined utility is not deployed, use component checks: budesonide-quality-checker, glycopyrronium-quality-checker, formoterol-quality-checker plus generic Lumex/LabEx checks.
FS-011Error handlingReturn explicit messages for missing file, empty CSV, invalid schema, output write failure and invalid format.

Example output.json

{
  "utilityId": "budesonide-glycopyrronium-formoterol-quality-checker",
  "utilityFolder": "BudesonideGlycopyrroniumFormoterolQualityChecker",
  "package": "Global/API coverage extension",
  "overallStatus": "PASS|WARNING|FAIL",
  "sourceFile": "input.csv",
  "processedAtUtc": "2026-07-02T00:00:00Z",
  "checks": [
    {
      "parameter": "BatchNumber",
      "value": "BGF-2026-001",
      "status": "PASS|WARNING|FAIL",
      "message": "Deterministic rule-based check result",
      "ruleReference": "FS-RULE-001"
    },
    {
      "parameter": "BudesonideAssay",
      "value": "160.0",
      "status": "PASS|WARNING|FAIL",
      "message": "Deterministic rule-based check result",
      "ruleReference": "FS-RULE-002"
    },
    {
      "parameter": "GlycopyrroniumAssay",
      "value": "9.0",
      "status": "PASS|WARNING|FAIL",
      "message": "Deterministic rule-based check result",
      "ruleReference": "FS-RULE-003"
    },
    {
      "parameter": "FormoterolAssay",
      "value": "4.5",
      "status": "PASS|WARNING|FAIL",
      "message": "Deterministic rule-based check result",
      "ruleReference": "FS-RULE-004"
    },
    {
      "parameter": "FineParticleFraction",
      "value": "20.5",
      "status": "PASS|WARNING|FAIL",
      "message": "Deterministic rule-based check result",
      "ruleReference": "FS-RULE-005"
    },
    {
      "parameter": "DDUDeviation",
      "value": "7.0",
      "status": "PASS|WARNING|FAIL",
      "message": "Deterministic rule-based check result",
      "ruleReference": "FS-RULE-006"
    },
    {
      "parameter": "Moisture",
      "value": "0.4",
      "status": "PASS|WARNING|FAIL",
      "message": "Deterministic rule-based check result",
      "ruleReference": "FS-RULE-007"
    },
    {
      "parameter": "Impurities",
      "value": "0.7",
      "status": "PASS|WARNING|FAIL",
      "message": "Deterministic rule-based check result",
      "ruleReference": "FS-RULE-008"
    },
    {
      "parameter": "ValveLeak",
      "value": "0.2",
      "status": "PASS|WARNING|FAIL",
      "message": "Deterministic rule-based check result",
      "ruleReference": "FS-RULE-009"
    },
    {
      "parameter": "ActuatorForce",
      "value": "19.0",
      "status": "PASS|WARNING|FAIL",
      "message": "Deterministic rule-based check result",
      "ruleReference": "FS-RULE-010"
    }
  ],
  "criticalFindings": [],
  "warnings": [],
  "audit": {
    "inputHash": "sha256:<calculated at runtime>",
    "rulesVersion": "<utility executable version>",
    "documentation": "BudesonideGlycopyrroniumFormoterolQualityChecker.documentation.html"
  }
}

Traceability matrix

URSFSTestEvidence
URS-001FS-001, FS-002OQ-001Verify execution and import of valid input.csv.
URS-002FS-005, FS-006OQ-004Repeat the same dataset and compare output.json.
URS-003FS-003, FS-004, FS-011OQ-002, OQ-003Verify missing columns and invalid types.
URS-004FS-005, FS-006OQ-004, PQ-001Verify critical deviations on real/boundary data.
URS-005FS-007, FS-009OQ-005Verify JSON schema and downstream-system suitability.
URS-006FS-008OQ-006Verify identifiers and audit metadata.
URS-007FS-008, FS-011IQ-001, OQ-007Verify documentation completeness and control evidence.
URS-008FS-005, FS-008, FS-010PQ-002Verify review workflow and no replacement of QA decision.

IQ/OQ/PQ test scenarios

IDScenarioExpected result
IQ-001Verify executable, input.csv, documentation and checksum availability.Delivery set is complete; version is recorded.
OQ-001Valid sample row from input.csv.PASS or acceptable WARNING according to rules.
OQ-002Remove a mandatory CSV column.Schema error or FAIL with missing-column reference.
OQ-003Place a non-numeric value into a numeric field.Type-conversion error with row/field reference.
OQ-004Set a critical parameter outside the limit.FAIL and critical finding.
OQ-005Verify output.json structure.All mandatory sections are present and JSON is valid.
OQ-006Verify batch/sample traceability.Input and result identifiers match.
OQ-007Verify fallback/decomposition for combined APIs.Component checks are explicitly documented.
PQ-001Verify 3–5 real user batches/samples.Result is confirmed by QC/QA review.
PQ-002Verify deviation workflow and manual QA decision.Utility supports review but does not replace approved decision.

QA/QC and change control

  • Do not rename columns without updating validator, documentation and test set.
  • Retain input.csv, output.json, executable version and checksum.
  • Before production use, perform IQ/OQ/PQ or equivalent CSV/CSA verification.
  • Critical limits shall be verified against the approved specification, registration dossier and local SOPs.
  • For combination products, document whether the specialized FDC utility or fallback component checks were used.
  • The utility provides structured QC decision support; final release decision remains with QA/QP and approved procedures.

Included in packages

Global API & Biosimilars QC Suite

Package for high-demand global APIs, generics and biosimilars, including fixed-dose combinations and biological products.

Open

Medical Gases QC Suite

Quality-control package for medical and pharmaceutical gases: oxygen, nitrogen, carbon dioxide, nitrous oxide, helium and mixtures.

Open

World API Extension QC Suite

Extended package for 130 additional high-demand APIs and biological products prepared as a market-coverage backlog.

Open